Kathryn B. Armstrong is an associate in the FDA and Life Sciences practice at King & Spalding. Kate focuses her practice on regulatory, legislative, and litigation issues concerning medical products, including drugs, medical devices, biologics and combination products.
Prior to joining the firm Kate spent 3 years as Regulatory Counsel in FDA’s Office of the Commissioner, in the Office of the Chief Scientist. While in the Commissioner’s Office, Kate helped develop high-level policy and agency guidance, responded to hearing requests, and addressed complex appeals of agency decision-making, regarding, for example, requests for product center designation, user fees, and de novo requests for device reclassification.
Kate also spent 2.5 years in the FDA’s drug center in the Office of Compliance, where she managed an international, multi-year project in partnership with the Asia Pacific Economic Cooperation that was aimed at enhancing global medical product quality and supply chain security.
After leaving FDA, Kate joined the Congressional Research Service as a legislative attorney specializing in food and drug law. In this capacity, Kate assisted Members of Congress, congressional committees, and their staff, on legal issues spanning the breadth of the Food, Drug, and Cosmetic Act. During her time on the Hill, Kate assisted legislators in preparing the FDA Reauthorization Act of 2017.
Kate also regularly counseled congressional clients on issues of significant national attention and concern, including drug pricing and importation, the opioid epidemic, and expanding access to experimental therapies for terminally ill patients.
- J.D., Washington University in St. Louis School of Law
- B.A., Emory University
- New York
Rate : $$$